← Human Trials & Peer-Reviewed Studies
Effect of acupuncture on vasoactive intestinal peptide in ischemic cerebrovascular diseases
Plain-language guide to PMID 10437215 (1997): randomized controlled trial of VIP (Vasoactive Intestinal Peptide) in 59 patients.
Key Facts
- PMID
- 10437215
- Journal
- Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
- Year
- 1997
- Study type
- Randomized Controlled Trial
- Authors
- Zhang X et al. (6 authors)
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at VIP (Vasoactive Intestinal Peptide).
Vasoactive intestinal peptide (VIP) appears to play an important role as a neurotransmitter or neuromediater in ischemic cerebrovascular diseases (ICVD).
The effect of acupuncture, which is used in treatment of ICVD with good efficiency, on VIP has not been known.
For finding the mechanism of acupuncture in treatment of ICVD and the effect of electro-acupuncture on VIP, the present study was performed.
Who Took Part
The abstract describes 59 patients taking part.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
59 patients with acute ICVD were randomly divided into two groups.
Electro-acupuncture and routine treatment were given in Group 1 (n = 29), and routine treatment was used alone in Group 2 (n = 30).
How the Study Was Run
The researchers set it up as a randomized study.
The patients were allocated by chance, so the VIP (Vasoactive Intestinal Peptide) group and the comparison group should start out alike.
The cerebrospinal fluid (CSF) and blood were taken before the beginning of treatment and after a course of treatment in both groups.
The control group consisted of 38 cases of non-ICVD.
VIP was measured by radioimmunoassay.
What Was Measured
PubMed files the paper under topics including Acupuncture Therapy, Brain Ischemia, Electroacupuncture and Vasoactive Intestinal Peptide.
What This Means in Plain Language
The paper is a randomized study of VIP (Vasoactive Intestinal Peptide) in 59 patients.
The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 1997 (Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan), a journal based in China.
More context: the VIP (Vasoactive Intestinal Peptide) compound page, all human trials.
Our Notes on the Compound
VIP (Vasoactive Intestinal Peptide): A 28-amino-acid neuropeptide that relaxes smooth muscle and calms immune activity; aviptadil is a synthetic form.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.